CTRI/2010/091/000444已完成2 期
Multi-center, randomized, double-blind, placebo-controlled study of two dosages of AM3301 for add-on treatment of mild to moderate active ulcerative colitis
Kemin Pharma0 个研究点目标入组 180 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Must sign and date written informed consent prior to any study-related procedures and, in the opinion of the investigator, be willing and likely to comply with all requirements of the study
- •2.Male or non-pregnant female subjects 18-65 years of age, inclusive
- •3.A history of UC for at least 6 months prior to screening
- •4.All subjects must have clinical and endoscopic confirmed diagnosis of active mild to moderate UC with disease extension beyond the rectum (>12 cm from the ano-rectal junction):
- •5.Confirmed by obligatory colonoscopy/ endoscopy at screening: full report to be available and score >2 (at least moderate friability)
- •6.Ulcerative Colitis Disease Activity Index [UCDAI] of 5-10, inclusive, as assessed on screening (based on retrospective recall by the subject over the previous 3 days) and to be confirmed after 7 days of baseline observation, before inclusion in the randomization procedure, and not improving ≥2 score points during the baseline period
- •7.Duration of current relapse less than 6 weeks from screening (according to subject)
- •8.Oral mesalazine/sulfasalazine maintenance therapy (<2g/day) for no less than 30 days prior to screening
- •9.Females of childbearing potential require a negative urine pregnancy test and must agree to abstinence or to use prescription contraceptives and to use a barrier contraceptive device along with a spermicidal product for the duration of the study. Subjects who are surgically sterile, menopausal or using contraceptive implants prior to the study enrolment are not required to utilize dual contraceptive techniques
- •10.Otherwise in generally good health as judged by the investigator
排除标准
- •1.Proctitis (<12 cm from the ano-rectal junction)
- •2.Indeterminate colitis
- •3.Crohn?s disease
- •4.Previous colonic surgery
- •5.Severe or fulminant UC [UCDAI >10] or requiring hospitalization
- •6.Evidence of other forms of inflammatory bowel disease
- •7.Subjects with a new diagnosis of UC
- •8.Subjects who altered their mesalazine/sulfasalazine dosage (dose regimen or dose) in the 2 weeks prior to screening
- •9.Subjects with a positive stool culture for any enteric pathogens that is clinically significant, pathogenic ova or parasites, or a positive EIA that is subsequently confirmed by a positive cytotoxin assay for C. difficile toxin
- •10.Subjects who have used the following medications within the specified period
- •a.Loperamide and other anti-diarrheal agents, probiotics, antibiotics: 1 week during run-in period
- •b.NSAIDs and COX-2 inhibitors, within 14 days from screening
- •c.Oral and injectable steroids, within 30 days from screening
- •d.Rectally administered mesalazine/sulfasalazine or other 5-ASAs or steroids, within 7 days from screening. Topical medications except for suppository and enemas are not excluded
- •e.Antivirals or antifungals within 30 days
- •f.Immunomodulating/suppressing drugs or biologicals (including anti TNF-α, cyclosporine, thalidomide, methotrexate) within 2 months
- •g.Sulfasalazine/mesalazine at higher dose than for maintenance treatment (higher than 2 g/day) within 30 days
- •11.Failing to respond to steroids within the previous year prior to screening
- •12.Subjects who have any other clinically significant disease(s) which, in the opinion of the investigator, could compromise the subject?s involvement in the study or overall interpretation of the data, such as mental/emotional disorder, dysplasia or cancer, seropositivity for HIV, HCV, uncontrolled hematologic, renal, hepatic, metabolic pulmonary or cardiovascular disease and active alcohol or drug abuse
- •13.Needing enemas to treat their disease or to maintain remission
- •14.Subjects with abnormal laboratory values at admission which are clinically significant by the investigator (outlier values outside the normal values are allowed and to be marked as ?NCS? if considered Not Clinically Significant (NCS) by the investigator based on the nature of the disease. Quite some UC subjects have an aberrant immune response and abnormal laboratory values due to the impaired absorption, and blood loss
- •15.Subjects whose UCDAI score decreases ≥2 during the 7-day run-in period
- •16.Allergy to aspirin or salicylate derivatives
- •17.Subject with a history of drug allergy in general or hypersensitivity to anti-inflammatory drugs
- •18.Participation in another clinical study within the last 3 months prior to screening
- •19.Inability to comply with the protocol requirements or to fill in the diary cards
- •20.Pregnancy or breast-feeding women or women of child-bearing potential not agreeing to birth control
研究者
相似试验
已完成
2 期
A clinical trial to study the effects of Bacillus subtilis strain PB6, as add-on to standard maintenance therapy in the treatment of mild to moderate ulcerative colitisCTRI/2009/091/000693Kemin Pharmaa division of Kemin Industries South Asia Pvt. Ltd.The Trapezium, No 39, Nelson Manickam Road, Chennai-600029, India
进行中（未招募）
不适用
Multi-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety and efficacy of Bimosiamose 5% Cream for the treatment of patients with chronic plaque type psoriasis - Psoriasis POCchronic plaque-type psoriasis (psoriasis vulgaris)MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2008-000197-20-DERevotar Biopharmaceuticals AG
已完成
2 期
Multi-center, randomized, double-blind, placebo-controlled phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patientsmucoviscidosis1002766410010613NL-OMON42435Bayer HealthCare AG5
进行中（未招募）
1 期
Safety and tolerability of BAY63-2521 in Cystic Fibrosis patientsCystic FibrosisEUCTR2013-004595-35-NLBayer HealthCare AG40
进行中（未招募）
不适用
Multi-center, randomized, double-blind, placebo-controlled, cross-over Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-017257-35-DERevotar Biopharmaceuticals AG77